Xencor, Inc.
Xencor develops engineered antibodies using XmAb technology for cancer and autoimmune diseases.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 2Latest story
November 2026
October 2026
August 2026
July 2026
Xencor develops engineered antibodies using XmAb technology for cancer and autoimmune diseases.
November 2026
October 2026
August 2026
July 2026